Acute severe colitis is a medical emergency and requires prompt treatment with intravenous steroids. Infliximab is typically used as rescue therapy in those who fail to respond to corticosteroids. This article outlines the altered pharmacokinetics of infliximab in acute severe UC and summarised the latest published data surrounding accelerated infliximab dosing.
- ulcerative colitis
- clinical decision making
- inflammatory bowel disease
Statistics from Altmetric.com
Contributors JF and SrS were involved in drafting and final revision of the manuscript. All authors involved (JF, TC, SrS and ShS) were involved in editing and approval of the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SrS has received speaker fee from Abbvie, Dr Falk Pharma, Shire, Takeda, Janssen and received educational grant from Abbvie, Actavis, Janssen, Takeda, Dr Falk Pharma and is an advisory board member for Abbvie, Dr Falk Pharma and Vifor Pharma.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.